Simon Skjøde Jensen Email & Phone Number

Kongens Lyngby, Capital Region, Dk

As CEO of MonTa Biosciences I have developed the company from a start-up to a full-blown clinical stage biotech company. I have enjoyed the exiting journey with a sharp learning curve of taking our technology from bench to bedside, and led the lead selection process, preclinical development, CMC activities and GLP tox studies and completing our Clinical Trial Protocol. We have now been running our clinical trial for 3 years with clinical sites in Belgium, Spain and Denmark, and dosed more than 40 patients and learned a lot about our lead drug MBS8. I have closed license agreements and five rounds of investments to MonTa, the most recent a series A investment to secure development and completion of our phase I clinical trial to find the optimal way to treat patients with MBS8. As CEO of MonTa Biosciences I am focused on creating value and bring our lead candidate timely to patients in need. The role as CEO involves management of our strong team and development of the company, high level overview of CMC activities, pharmacology studies, biomarker and regulatory strategy and process, business development, finance and contracts, intellectual property strategy and licensing. With accumulating clinical data we are in the strategic process on further clinical development which is very exciting and challenging considering the multitude of opportunities for clinical development in the space between unmet medical needs, current standard of care, commercial opportunities and the competitive space in the given indication on e.g. patient recruitment. Please visit www.montabiosciences.com

Kgs. Lyngby, Danmark, Dk

I was key in the innovative process of spinning out a new type of cancer immunotherapy technology from DTU Nanotech to establish the biotech Company MonTa Biosciences. Tasks included working with innovation, collaborations, setting up strategic research partnerships, advisors and supervisor for stakeholders, negotiating contracts and license agreements, communicating, presenting and negotiating with investors, establishing BoD, negotiating and handling investment process including contract discussions and execution, attraction of soft funding, reporting to granting bodies, and fianlly management of RnD-projects to develop the cancer immunotherapy technology to obtain PoC.

Hørsholm, Dk

Management of the steering Group for the Innovation Consortium "Treg-Centre" involving major Pharma and biotech Companies, and leading university partners.

Hørsholm, Dk

• People management of research scientists, technicians and students• Responsible for establishment of projects with national and international partners, secure appropriate project delivery and reporting to Danish and EU authorities• Customer related activities involving marketing material, presentations, meetings, quotations, accomplish assignments, datahandling and interpretation, preparation of final reports • Grant proposals, applications, implementation and reporting• Writing patents and particitate in the filing process• Prepare manuscripts and publications2011-13: Awarded an EU grant under the EUREKA-EUROSTARS programme as partner and workpackage manager. The project involves R&D within delivery technologies towards immune cells to modulate their response 2009-12: Steering group manager in the Innovation Consortia "Treg-center" working on regulatory T-cell screening models and Treg markers. Collaboration with Karolinska University Hospital, University of Southern Denmark and private companies with interest in the Treg-field 2007-10: Innovation Consortia Manager "Center for Immunomics", working on dendritic cell models and screening of immunomodulatory compounds, drugs and microorganisms involved in innate and adaptive immune responses 2007-11: Awarded a Strategic Research Grant in collaboration with DTU Nanotech on drug-delivery projects involving liposomal drug delivery to cancer and immune cells2007-present: Supervisor of PhD students and Master students

Hørsholm, Dk

I was spearheading the Eurostars project "LIPODEL" from idea to setup partners as well as drafting and submitting grant proposal. The project was an innovative ambitious project between three biotech Companies and the Technical University of Denmark. The project resulted in patent applications, publications and generation of new product candidates within the immuno-oncology area.

Hørsholm, Dk

Management and spearheading the Innovation Consortium "Centre for Immunomics" with participation of major pharma, biotech and ingredients companies and leading universities with interest in immunomodulation and dendritic cells. Management and communication with funding bodies and project stakeholders. The project reached major goals for both commercial and academic milestones including publications, establishment of advanced immune cell models for screening of immune modulating drugs, bacteria and probiotics, and spin-out of commercially attractive novel therapeutic targets for immunotherapy.

Hørsholm, Dk

I was managing the Innovation Consortium CNP as an innovative project between major Danish Pharma and Biomedico companies and Risø National Research Laboratory. The aim was to investigate novel surfaces supporting cell growth and differentiation, establish state-of-the art methodoligies to test for biocompatibility of surfaces and Medical devices for clinical use. The project resulted in several publications and establishment of services for the biomedical and Pharma industry.

Dk

Responsible for in vitro and in vivo Proof of Principle of the liposomal drug delivery technology proprietary to LiPlasome, involving sPLA2-mediated site-specific degradation og liposomes and release of the encapsulated drug.Design and experience with cancer models involving xenograft and syngenic mouse models.Involved in strategic decisions and development of new technologies like pro-drug design, liposomal design and understanding.Evaluation of cancer drugs suitable for liposomal drug delivery and as prodrug candidates using the LiPlasome technology.Evaluation and innovation to discover and develop drug delivery, site specific release and targeting technologies. Initiated NCI (National Cancer Institute) contact and collaboration and obtained NCI interest in a CRADA between LiPlasome and NCI

PhD project; research focused on Vitamin D and analogues analyzing the effect on cell cycle regulation. Supervised by Professor, Dr Med Jiri Bartek, and Head of Section, PhD, Mogens Winkel MadsenGained experience from a world class leading laboratory at the Danish Cancer Society, and from the pharmaceutical industry (LEO-Pharma)

København Ø, Dk

Master studies at Jiri Barteks group at the Danish Cancer Society. Main research area was regulation of the cell cycle, involving mainly CDK regulation and function

Elite athlete and part of the National Danish road racing team in cycling. Twice Danish Champion and Danish Record holder in road racing. Participated in a number of championships and key races and criteriums.

Phd, Cell Biology/Molecular Biology

M.Sc, Biotechnology

Course On Leading Breakthrough Innovation